MRI引导下经会阴与经直肠认知融合靶向前列腺穿刺对PI-RADS 3-5病灶的前列腺癌检出率比较
回顾性单中心研究纳入482例PI-RADS 3-5病灶男性,比较MRI引导下穿刺、认知融合经会阴穿刺和认知融合经直肠超声引导穿刺的检出率。三种方法在PI-RADS 3、4、5病灶中检出前列腺癌及有临床意义前列腺癌均无显著差异。结论认为mpMRI发现异常病灶比穿刺技术选择对提高检出更重要。
要点
- 三种靶向穿刺方法在PI-RADS 3-5病灶中检出前列腺癌无显著差异
- 三种方法检出有临床意义前列腺癌也无显著差异
- 病灶位置或大小不影响三种方法的检出差异
核心结论
- MRI引导下穿刺、认知融合经会阴穿刺和认知融合经直肠超声引导穿刺检出前列腺癌或有临床意义前列腺癌的能力无显著差异。
- mpMRI发现异常区域对提高前列腺癌检出似乎比选择穿刺技术更重要。
研究设计与样本
- 回顾性单中心研究连续纳入在一位有经验泌尿外科医生私人诊所接受MRI引导下穿刺及在另一位有经验泌尿外科医生处接受认知融合经会阴和认知融合经直肠超声引导穿刺的PI-RADS 3-5病灶男性。
- 共482例男性、595个靶向mpMRI病灶、483次穿刺。
- MRI引导下穿刺298次,认知融合经会阴穿刺248次,认知融合经直肠超声引导穿刺49次。
主要发现
- PI-RADS 3病灶前列腺癌检出率分别为48.9%、40.0%和44.4%,无显著差异。
- PI-RADS 4病灶前列腺癌检出率分别为73.2%、81.0%和85.0%,无显著差异。
- PI-RADS 5病灶前列腺癌检出率分别为95.2%、92.0%和95.0%,无显著差异。
- PI-RADS 3病灶有临床意义前列腺癌检出率分别为42.2%、30.0%和33.3%,无显著差异。
- PI-RADS 4病灶有临床意义前列腺癌检出率分别为66.8%、66.0%和80.0%,无显著差异。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为三种靶向穿刺方法检出前列腺癌或有临床意义前列腺癌的能力无显著差异。
- 作者结论认为mpMRI发现异常区域对提高前列腺癌检出似乎比穿刺技术选择更重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the detection rates of prostate cancer (PCa) in men with Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 abnormalities on 3-Tesla multiparametric (mp) magnetic resonance imaging (MRI) using in-bore MRI-guided biopsy compared with cognitively directed transperineal (cTP) biopsy and transrectal ultrasonography (cTRUS) biopsy. METHODS: This was a retrospective single-centre study of consecutive men attending the private practice clinic of an experienced urologist performing MRI-guided biopsy and an experienced urologist performing cTP and cTRUS biopsy techniques for PI-RADS 3-5 lesions identified on 3-Tesla mpMRI. RESULTS: There were 595 target mpMRI lesions from 482 men with PI-RADS 3-5 regions of interest during 483 episodes of biopsy. The abnormal mpMRI target lesion was biopsied using the MRI-guided method for 298 biopsies, the cTP method for 248 biopsies and the cTRUS method for 49 biopsies. There were no significant differences in PCa detection among the three biopsy methods in PI-RADS 3 (48.9%, 40.0% and 44.4%, respectively), PI-RADS 4 (73.2%, 81.0% and 85.0%, respectively) or PI-RADS 5 (95.2, 92.0% and 95.0%, respectively) lesions, and there was no significant difference in detection of significant PCa among the biopsy methods in PI-RADS 3 (42.2%, 30.0% and 33.3%, respectively), PI-RADS 4 (66.8%, 66.0% and 80.0%, respectively) or PI-RADS 5 (90.5%, 89.8% and 90.0%, respectively) lesions. There were also no differences in PCa or significant PCa detection based on lesion location or size among the methods. CONCLUSION: We found no significant difference in the ability to detect PCa or significant PCa using targeted MRI-guided, cTP or cTRUS biopsy methods. Identification of an abnormal area on mpMRI appears to be more important in increasing the detection of PCa than the technique used to biopsy an MRI abnormality.
引用
- Yaxley AJ, Yaxley JW, Thangasamy IA, et al. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. BJU Int. 2017. PMID: 28749035. doi:10.1111/bju.13971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。